HORMONAL REGULATORS OF MUSCLE AND METABOLISM IN AGING (HORMA)--1 R01 AG18169-01

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 老年人经历骨骼肌质量、肌肉力量、日常生活活动的功能能力的逐渐丧失，情绪受损，并最终失去独立性。 衰老还与性腺功能和生长激素（GH/IGF-反应）完整性的丧失有关。 然而，这些激素轴的缺乏与肌肉减少症和衰老中的虚弱的关系尚未建立，或者这两种激素系统在维持正常肌肉质量和功能方面是否存在相互作用。我们假设这两种激素系统通过不同的互补机制调节肌肉骨骼蛋白质质量和收缩纤维，并且睾酮和GH/IGF-1的最佳水平对于维持骨骼肌质量、肌肉力量、日常生活的全功能活动、生活质量和衰老过程中的独立性是必要的。 这项研究的结果应导致重要的机制的理解，雄激素缺乏和低促生长性的相对贡献，老年人与肌肉质量和力量下降有关的脆弱。这些结果还为将来测试新的、新颖的治疗策略提供了有价值的信息，这些治疗策略在与年龄相关的肌肉减少症伴虚弱中比胃肠外治疗更耐受和方便。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Elderly persons experience progressive loss of skeletal muscle mass, muscle strength, functional capacity for activities of daily living, have impaired mood, and eventually lose independence. Aging is also associated with a loss of gonadal function and integrity of the growth hormone (GH/IGF-laxis. However, the relationship of deficiencies of these hormones axes to sarcopenia and frailty in aging has not been established or whether there is an interactions of these two hormone systems in maintaining normal muscle mass and function. We hypothesize that both hormone systems regulate musculoskeletal protein mass and contractile fibers by different and complimentary mechanisms and that optimal levels of both testosterone and GH/IGF-1 are necessary to maintain skeletal muscle mass, muscular strength, full functional activities of daily living, quality of life, and independence during the aging process. The findings of this study should result in important mechanistic understanding of the relative contributions of androgen deficiency and hyposomatotropism in elderly persons with frailty related to decreased muscle mass and strength. The results should also provide valuable information for future testing of new, novel treatment strategies which are more tolerable and convenient than parenteral therapies in age associated sarcopenia with frailty.